REG - OptiBiotix Health - Directorate Change

OptiBiotix HealthAnnouncement

21/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230221:nRSU4878Qa&default-theme=true

RNS Number : 4878Q  OptiBiotix Health PLC  21 February 2023

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Directorate change

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, cardiovascular disease, diabetes and skincare,
announces that René Kamminga a Director of the Company and CEO of OptiBiotix
Ltd, a wholly owned subsidiary of OptiBiotix Health plc, will leave the
business on 28 February 2023 to pursue other opportunities.  Stephen O'Hara,
CEO of OptiBiotix Health plc will resume the role as CEO of OptiBiotix Ltd and
will lead a minor restructuring of the business, with further announcements to
be made in due course.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "I would like to thank René for
his contribution since his appointment in March 2021 and wish him well in his
next move. René has helped develop the OptiBiotix business leading the
transition from distributor to more direct selling and broadening the product
portfolio with the addition of Opti-XOS and WellBiome®.  He has been
instrumental in opening up business opportunities in the US, Middle east, and
Asia Pacific which we hope will mature into number of key accounts in 2023.
René has helped build resilience and greater opportunity within the
OptiBiotix portfolio creating the potential for building significant sales and
shareholder value as we move through 2023 and beyond."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Joint Broker)              Tel: 020 7397 8900
 Callum Davidson
 Michael Johnson / Russell Kerr (Sales)

 Peterhouse Capital Limited (Joint Broker)         Tel: 020 7220 9797
 Duncan Vasey/ Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions.  These forward looking statements are
not based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures (including the
amount, nature and sources of funding thereof), competitive advantages,
business prospects and opportunities. Such forward looking statements reflect
the Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQBLFLXLLLBBK